KLOW (KPV 10mg/GHK-Cu 50mg/BPC-157 10mg/TB-500 10mg)

Description

KLOW is a co-lyophilized blend of four separately characterized compounds — KPV 10mg, GHK-Cu 50mg, BPC-157 10mg and TB-500 (thymosin β4) 10mg — supplied as a lyophilized powder in a single sealed vial containing 80mg combined net content. “KLOW” is the catalog designation for this combination (the GLOW blend with KPV added); it is not a compound name and carries no meaning beyond identifying the blend. Each lot is analyzed by HPLC and mass spectrometry; the certificate of analysis for the current lot is shown in the product images and in the COA library. Each compound is also available as a single-compound listing.

KLOW blend specifications

KLOW research background

KPV is the C-terminal tripeptide (residues 11–13) of α-melanocyte-stimulating hormone, identified in the 1980s and 1990s as the shortest α-MSH fragment retaining activity in cell-culture and animal inflammation models (Hiltz and Lipton and later groups). GHK-Cu is the copper complex of a plasma tripeptide first isolated by Loren Pickart in 1973 and studied in cell-culture and animal-tissue models of extracellular-matrix synthesis. BPC-157 is a synthetic gastric-protein fragment studied chiefly in rat models by a single Zagreb group, and thymosin β4 is a ubiquitous intracellular actin-sequestering protein with a broad independent literature in cell-migration and animal wound models. These are laboratory findings in cells and animals; they have not been replicated in controlled human trials, and no conclusions about human effects should be drawn from them.

Analytically a four-component blend should be read with care. A single purity percentage for a mixture is not meaningful on its own; the useful information on the COA is that the HPLC trace resolves four principal peaks in the expected proportions and that the mass spectrum shows the four expected masses (≈ 342, ≈ 404, ≈ 1420 and ≈ 4963, with Tβ4 appearing as a deconvoluted multiply-charged envelope). KPV, being the smallest and most polar component, elutes earliest on a reversed-phase gradient and is the one most easily lost under the solvent front if the method is not stated.

Handling and storage: Lyophilized powder in a sealed vial. Store at −20 °C for long-term storage or at 2–8 °C for short-term storage, protected from light and moisture. Allow the vial to reach room temperature before opening to prevent condensation.

Disclaimer: This product is furnished strictly for in-vitro laboratory research. It is not a drug, has not been evaluated or approved by the FDA, and is not intended for human or animal consumption or for any medical, veterinary, diagnostic, cosmetic or household use. The research background above summarizes the published literature for the benefit of researchers; it does not describe, and must not be read as describing, any effect in or use by humans.